USNA compared with DFTX: revenue, margins and what each company keeps, and the suppliers and customers both name

USNAUsana Health Sciences Inc

Mkt capRevenueRevenue

DFTXDefinium Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

USNAUsana Health Sciences Inc

DFTXDefinium Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

USNA

1 of 3at or beyond implied

Reportimpliedrealized× implied

Nov 4 '26—▼−3.63%—

Q2 FY26±19.6%▼−34.20%×1.74

Q1 FY26±21.5%▲+3.89%×0.18

Feb 18 '26±18.9%▼−8.03%×0.42

DFTX

0 of 3at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±20.9%0.00%×0.00

May 8 '26±9.7%▼−4.96%×0.52

= impliedUSNA realized, solidDFTX realized, hatchedOne scale, both sides: full bar = 35%× = |realized| ÷ impliedSource: market data

Q1 FY26

±12.9%

▲+0.93%

×0.07

Jan 12 '26—▲+0.29%—

USNAUsana Health Sciences Inc

13.91· pre 13.96· delayed

Mkt cap$264.8MRevenue$223MQ2 FY26Revenue$925MFY25

DFTXDefinium Therapeutics, Inc.

30.34· pre 30.53· delayed

Pre-marketNov 6 '26delayed

Mkt cap$4.4BRevenue—Revenue—

Compare

Pre-marketNov 6 '26delayed

USNAUsana Health Sciences Inc

DFTXDefinium Therapeutics, Inc.

13.91pre 13.96delayed

Price

30.34pre 30.53delayed

$264.8M

Mkt cap

$4.4B

Q2 FY26$223M

Revenue

—

FY25$925M

Revenue

—

USNA13.91vsDFTX30.34Pre-marketNov 6 '26delayed